Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

De-risking the Investigational New Drug (IND) process

Summary by European Pharmaceutical Manufacturer
Boyds’ chief development officer, Dr Nick Meyers, and director of regulatory affairs, Dr Eric Hardter, provide advice and guidance to drug developers and sponsors on de-risking the Investigational New Drug (IND) process.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

European Pharmaceutical ManufacturerEuropean Pharmaceutical Manufacturer

De-risking the Investigational New Drug (IND) process

Boyds’ chief development officer, Dr Nick Meyers, and director of regulatory affairs, Dr Eric Hardter, provide advice and guidance to drug developers and sponsors on de-risking the Investigational New Drug (IND) process.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

European Pharmaceutical Manufacturer broke the news in on Monday, October 13, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Boyds icon

Boyds

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal